Pharmacodynamic and early clinical studies with velnacrine.
The paper reviews the results obtained with velnacrine, a cholinesterase inhibitor and potential Alzheimer's disease agents, in early clinical studies in healthy volunteers and patients with probable Alzheimer's disease (AD). In healthy subjects, the compound was demonstrated to reverse cognitive impairment induced by scopolamine. Single doses of velnacrine improved performance of patients with AD in simple recognition tasks and enhanced regional cerebral blood flow in prefrontal-parietal areas. In a short crossover-study, velnacrine was demonstrated to be significantly (< 0.05) superior to placebo in the cognitive behaviour subscale of the ADAS, a word recognition task and, in trend, also on the Clinical Global Impression of Improvement.
Siegfried
K R
KR
Central Clinical Research/Neuroscience, Hoechst AG, Frankfurt am Main, Germany.
D000544:Alzheimer Disease / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D002800:Cholinesterase Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D003072:Cognition Disorders / Q000139:chemically induced / Q000517:prevention & control; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D010919:Placebos; D012601:Scopolamine; D013619:Tacrine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D015899:Tomography, Emission-Computed, Single-Photon
D002800:Cholinesterase Inhibitors; D010919:Placebos; D013619:Tacrine; D012601:Scopolamine; C056424:velnacrine